MX2024001843A - Composición farmacéutica y método para tratar o prevenir cáncer. - Google Patents
Composición farmacéutica y método para tratar o prevenir cáncer.Info
- Publication number
- MX2024001843A MX2024001843A MX2024001843A MX2024001843A MX2024001843A MX 2024001843 A MX2024001843 A MX 2024001843A MX 2024001843 A MX2024001843 A MX 2024001843A MX 2024001843 A MX2024001843 A MX 2024001843A MX 2024001843 A MX2024001843 A MX 2024001843A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- hla
- pharmaceutical composition
- cancer
- prevention
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 abstract 7
- 108010075704 HLA-A Antigens Proteins 0.000 abstract 7
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 abstract 4
- 108010052199 HLA-C Antigens Proteins 0.000 abstract 4
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 abstract 2
- 108010058607 HLA-B Antigens Proteins 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 108091005601 modified peptides Proteins 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A61K39/4615—
-
- A61K39/4622—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A61K39/464453—
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente descripción incluye una composición farmacéutica para tratar o prevenir un cáncer en un sujeto positivo para HLA-A*11:01, HLA-A*02:01, HLA-A*02:06, HLA-A*02:07, HLA-A*26:01, HLA-A*26:03, HLA-A*01:01, HLA-B*15:01, HLA-B*35:01, HLA-C*03:03, HLA-C*05:01, HLA-C*07:01, o HLA-C*07:02 que comprende un péptido que consiste en la secuencia de aminoácidos de WAPVLDFAPPGASAYGSL (SEQ ID NO: 2) o un péptido alterado del mismo que tiene una capacidad de inducir CTL o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021131636 | 2021-08-12 | ||
| PCT/JP2022/030546 WO2023017836A1 (ja) | 2021-08-12 | 2022-08-10 | 癌を処置または予防するための医薬組成物および方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001843A true MX2024001843A (es) | 2024-05-16 |
Family
ID=85200603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001843A MX2024001843A (es) | 2021-08-12 | 2022-08-10 | Composición farmacéutica y método para tratar o prevenir cáncer. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4385519A1 (es) |
| JP (1) | JPWO2023017836A1 (es) |
| KR (1) | KR20240046880A (es) |
| CN (1) | CN118076382A (es) |
| AU (1) | AU2022327884A1 (es) |
| CA (1) | CA3228494A1 (es) |
| MX (1) | MX2024001843A (es) |
| TW (1) | TW202315645A (es) |
| WO (1) | WO2023017836A1 (es) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2280031B1 (en) | 1998-07-31 | 2015-04-15 | International Institute of Cancer Immunology, Inc. | Cancer antigens based on products of the tumor suppressor gene WT1 |
| IL142216A0 (en) | 1998-09-30 | 2002-03-10 | Corixa Corp | A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same |
| US20030072767A1 (en) | 1998-09-30 | 2003-04-17 | Alexander Gaiger | Compositions and methods for WT1 specific immunotherapy |
| US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| CN1281625C (zh) | 2001-03-22 | 2006-10-25 | 株式会社癌免疫研究所 | 经修饰的wt1肽 |
| US7553494B2 (en) | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
| JP4365784B2 (ja) | 2002-06-12 | 2009-11-18 | 株式会社癌免疫研究所 | Ｈｌａ−ａ２４拘束性癌抗原ペプチド |
| ATE442378T1 (de) | 2002-09-20 | 2009-09-15 | Int Inst Cancer Immunology Inc | Substituierte wt1-peptide |
| CA2544214C (en) | 2003-11-05 | 2018-08-28 | International Institute Of Cancer Immunology, Inc. | Hla-dr-binding antigen peptide derived from wt1 |
| EP1708732B2 (en) | 2003-12-01 | 2016-05-18 | Sloan-Kettering Institute For Cancer Research | Synthetic hla binding peptide analogues and uses thereof |
| ES2507097T3 (es) | 2005-01-19 | 2014-10-14 | Sumitomo Dainippon Pharma Co., Ltd. | Composición emulsionada para dilución y composición de vacuna contra el cáncer |
| ES2531142T3 (es) | 2005-10-17 | 2015-03-11 | Sloan Kettering Inst Cancer | Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden |
| PT1961761E (pt) | 2005-11-30 | 2010-12-16 | Chugai Pharmaceutical Co Ltd | Novos compostos peptídicos do tumor de wilms |
| EP3834836A1 (en) | 2006-04-10 | 2021-06-16 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and uses thereof |
| US20110318380A1 (en) | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
| AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
| CA2892660C (en) | 2012-12-17 | 2022-02-15 | Otsuka Pharmaceutical Co., Ltd. | Method for activating helper t cell |
| SG11201507883SA (en) | 2013-03-29 | 2015-10-29 | Sumitomo Dainippon Pharma Co Ltd | Wt1-antigen peptide conjugate vaccine |
| WO2014157704A1 (ja) | 2013-03-29 | 2014-10-02 | 大日本住友製薬株式会社 | Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン |
| WO2016093326A1 (ja) | 2014-12-11 | 2016-06-16 | 株式会社癌免疫研究所 | 血管新生病の免疫療法 |
| JPWO2018181648A1 (ja) | 2017-03-30 | 2020-02-13 | 大日本住友製薬株式会社 | Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体 |
| WO2019131722A1 (ja) | 2017-12-27 | 2019-07-04 | 大日本住友製薬株式会社 | Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物 |
| EP3954382A4 (en) * | 2019-04-05 | 2022-12-21 | Sumitomo Pharma Co., Ltd. | WATER-SOLUBLE ADJUVANT, AND COMPOSITION COMPRISING THE SAME |
| CN113966326A (zh) * | 2019-04-05 | 2022-01-21 | 大日本住友制药株式会社 | 水溶性佐剂 |
| JP7244446B2 (ja) | 2020-02-18 | 2023-03-22 | Kddi株式会社 | データ保管装置、データ保管方法及びコンピュータプログラム |
-
2022
- 2022-08-10 CA CA3228494A patent/CA3228494A1/en active Pending
- 2022-08-10 TW TW111130067A patent/TW202315645A/zh unknown
- 2022-08-10 AU AU2022327884A patent/AU2022327884A1/en active Pending
- 2022-08-10 EP EP22855898.7A patent/EP4385519A1/en active Pending
- 2022-08-10 JP JP2023541458A patent/JPWO2023017836A1/ja active Pending
- 2022-08-10 MX MX2024001843A patent/MX2024001843A/es unknown
- 2022-08-10 CN CN202280068176.3A patent/CN118076382A/zh active Pending
- 2022-08-10 WO PCT/JP2022/030546 patent/WO2023017836A1/ja active Application Filing
- 2022-08-10 KR KR1020247007574A patent/KR20240046880A/ko unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022327884A1 (en) | 2024-02-22 |
| JPWO2023017836A1 (es) | 2023-02-16 |
| CA3228494A1 (en) | 2023-02-16 |
| CN118076382A (zh) | 2024-05-24 |
| KR20240046880A (ko) | 2024-04-11 |
| WO2023017836A1 (ja) | 2023-02-16 |
| TW202315645A (zh) | 2023-04-16 |
| EP4385519A1 (en) | 2024-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI9814499B8 (pt) | Peptídeo amida opióide sintético ou um sal farmaceuticamente aceitavel do mesmo, e, composição farmacêutica | |
| US10590179B2 (en) | Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells | |
| NO20022531L (no) | Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer | |
| MX337756B (es) | Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo. | |
| CN110536898A (zh) | 用于治疗糖尿病的肽及方法 | |
| MX2021010404A (es) | Anticuerpos que se unen a una forma escindida de calreticulina mutante, y agente de diagnostico, preventivo o terapeutico para las neoplasias mieloproliferativas. | |
| Garcia‐Redondo et al. | Vascular effects of egg white‐derived peptides in resistance arteries from rats. Structure–activity relationships | |
| MX2024001843A (es) | Composición farmacéutica y método para tratar o prevenir cáncer. | |
| ATE326981T1 (de) | Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
| NO20043210L (no) | Tolerogene peptider fra myelin-basisprotein | |
| JP2021529181A (ja) | 癌特異的ｔ細胞受容体 | |
| MX2021001507A (es) | Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer. | |
| MX2011004176A (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo. | |
| EP4435001A3 (en) | Crf2 receptor agonists and their use in therapy | |
| BR112022004477A2 (pt) | Imunoterapêutico para tratamento de câncer de próstata | |
| RU2007115411A (ru) | Пептиды hsp60 и их apl-производные и фармацевтические композиции | |
| MXPA04001976A (es) | Hormona de crecimiento humano modificada. | |
| MX2022003598A (es) | Composicion farmaceutica, que comprende la proteina galectina 9 recombinante estabilizada, para la prevencion o el tratamiento de la artritis reumatoide y enfermedades oseas. | |
| GB2407321A (en) | Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor | |
| JP2003512388A (ja) | 免疫治療で使用される修飾ペプチドおよびペプチド模倣体 | |
| MX2022014249A (es) | Composición farmacéutica para tratar el cáncer. | |
| BR112022005782A2 (pt) | Proteína galectina 9 estabilizada recombinante, vetor recombinante, transformante, composição farmacêutica para prevenção ou tratamento de uma doença óssea, alimento funcional de saúde para prevenção ou melhora de uma doença óssea, e, uso de uma proteína galectina 9 estabilizada recombinante | |
| MX2023005135A (es) | Peptidos y metodos de uso. | |
| MX2023005395A (es) | Formulaciones de peptidos y metodos de uso. | |
| MX2020010085A (es) | Formulaciones que contienen péptidos. |